Brief: Valneva Provides Update On Recommendation For Use Of Its Chikungunya Vaccine By French Authorities
26/04/2025 18:45
April 26 (Reuters) - Valneva SE VLS.PA: VALNEVA PROVIDES UPDATE ON RECOMMENDATION FOR USE OF ITS CHIKUNGUNYA VACCINE BY FRENCH AUTHORITIES VALNEVA SE: ON APRIL 25, FRENCH HEALTH AUTHORITIES DECIDED TO SUSPEND USE OF IXCHIQ® IN PERSONS AGED 65 YEARS AND OLDER PENDING FURTHER INVESTIGATION VALNEVA SE - THREE SAES, INCLUDING ONE DEATH, REPORTED AFTER IXCHIQ VACCINATION VALNEVA SE - HAS MAINTAINS IXCHIQ RECOMMENDATION FOR AGES 18-64 Source text: ID:nGNX4TWdBd Further company coverage: VLS.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency